首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1767714

抗疟疾药市场按药物类别、给药途径、分销管道和地区划分

Anti-malarial Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

出版日期: 2025年06月12日 | 出版商:

Coherent Market Insights | 英文 162 Pages | 商品交期: 2-3个工作天内

价格

简介目录

抗疟疾药市场规模预计在 2025 年达到 10.812 亿美元，预计到 2032 年将达到 14.714 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 4.5%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	10.812亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	4.50%	2032年价值预测	14.714亿美元

疟疾原虫，是造成广泛感染疾病的原因。这种寄生虫会透过被感染的雌性疟蚊叮咬进入人体，并传播到肝臟并在那里产生寄生虫。人类疟疾通常由五种原生动物寄生虫引起：恶性疟原虫、三日疟原虫、卵形疟原虫、间日疟原虫和诺氏疟原虫。这些寄生虫中最危险的是疟疾原虫和疟疾原虫，它们是造成疟疾死亡的主要原因。抗疟疾药用于治疗和预防疟疾感染。大多数抗疟疾药针对疟疾感染的红血球期，即导致症状性疾病的感染期。早期诊断和有效治疗是控制疟疾的关键措施。治疗疟疾的药物种类繁多，包括奎宁、Chloroquine、甲氟喹、氯胍和伯氨喹。此外，乙胺嘧啶和磺胺多辛、蒿甲醚和卢米凡特林等复方药物也常用于治疗疟疾。

市场动态

疟疾治疗的研发活动正在兴起，预计这将在预测期内推动市场成长。此外，各种疟疾治疗药物正在进行临床试验，预计这也将在预测期内推动市场成长。此外，各药厂正积极参与研发活动，以开发用于治疗疟疾的新型药物。例如，2022 年 11 月，跨国製药公司诺华公司和抗疟药物研发领域的产品开发伙伴关係组织「疟疾抗疟疾药研发基金」（MMV）宣布，他们决定进入一种新型非青蒿素组合药物的 3 期试验，该药物用于治疗併发症疟疾。这种新型组合药物是卢米凡特林的优化配方，可以每天服用一次，而不是通常的每天两次。全球正在出现对现有疟疾治疗药物的抗药性，需要新的药物来继续根除疟疾的斗争。

本研究的主要特点

本报告对全球抗疟疾药市场进行了详细分析，并以 2024 年为基准年，给出了预测期 2025-2032 的市场规模和年复合成长率（CAGR%）。
它还强调了不同领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，对全球抗疟疾药市场的主要企业进行分析。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
全球抗疟疾药市场报告涉及该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
相关人员可以透过用于分析全球抗疟疾药市场的各种策略矩阵来促进他们的决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 1,081.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	4.50%	2032 Value Projection:	USD 1,471.4 Mn

Plasmodium parasites, a protozoan parasite, are the cause of the widespread infectious disease malaria. A parasite enters the body through the bite of an infected female Anopheles mosquito, which then travels to the liver, where the parasite is produced. Human malaria are generally caused by five types of plasmodium parasites, including P. falciparum, P. malariae, P. ovale, P. vivax, and P.knowlesi. The most dangerous parasite species among these are P. falciparum and P. vivax, which are also the ones responsible for the majority of malaria deaths. Antimalarial drugs are used for the treatment and prevention of malaria infection. Most antimalarial drugs target the erythrocytic stage of malaria infection, which is the phase of infection that causes symptomatic illness. Early diagnosis and efficient treatment are crucial measures to control malaria. Different types of drugs such as quinine, chloroquine, mefloquine, proguanil, primaquine, and others are used in the treatment of malaria. Moreover, some combination drugs such as Pyrimethamine & sulfadoxine, Artemether & lumefantrine, and others are also prescribed for treating the disease.

Market Dynamics

The ongoing research and development for malarial treatment is expected to fuel growth of the market in the forecast period. Various drugs are undergoing the clinical trial for the malarial treatment, which is also expected to drive the market during the forecast period. Moreover, various pharmaceutical companies are actively participating in research and development activities, in order to develop novel drug entity for treatment of malaria. For instance, in November 2022, Novartis AG, a multinational pharmaceutical corporation and Medicines for Malaria Venture (MMV), a product development partnership in the field of antimalarial drug research and development announced decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated malaria. This novel combination also contains an optimized formulation of lumefantrine, which allows it to be given once daily versus the usual twice-daily administration. As the world faces emerging resistance to current malaria treatments, new medicines are needed to continue the fight toward elimination.

Key features of the study:

This report provides in-depth analysis of the global anti-malarial drugs market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global anti-malarial drugs market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Ipca Laboratories Ltd., Zydus Group, Merck KGaA, Pfizer Inc., GSK plc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Alvizia Health Care, Bayer AG, and F. Hoffmann-La Roche Ltd.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global anti-malarial drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-malarial drugs market

Detailed Segmentation:

Global Anti-malarial Drugs Market, By Drug Class:
- Aminoquinolines
- Quinoline-methanol (4-quinolinemethanols)
- Cinchona Alkaloids
- Biguanides
- Sulfonamides and sulfones
- Others
Global Anti-malarial Drugs Market By Route of Administration:
- Oral
- Injectable
Global Anti-malarial Drugs Market By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Anti-malarial Drugs Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Ipca Laboratories Ltd.
- Zydus Group
- Merck KGaA
- Pfizer Inc.
- GSK plc.
- Cipla Inc.
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Alvizia Health Care
- Bayer AG
- Hoffmann-La Roche Ltd

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Anti-malarial Drugs Market, By Drug Class, 2020-2032 (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032(%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Aminoquinolines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Quinoline-methanol (4-quinolinemethanols)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Cinchona Alkaloids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Biguanides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Sulfonamides and sulfones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

5. Global Anti-malarial Drugs Market, By Route of Administration, 2020-2032 (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032(%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Global Anti-malarial Drugs Market, By Distribution Channel, 2020-2032 (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032(%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global Anti-malarial Drugs Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032(%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
North America
- Market Size and Forecast, By Drug Class, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, 2020-2032, (US$ Mn)
  - U.S.
  - Canada
Latin America
- Market Size and Forecast, By Drug Class, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, 2020-2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Size and Forecast, By Drug Class, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, 2020-2032, (US$ Mn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Class, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, 2020-2032, (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of APAC
Middle East
- Market Size and Forecast, By Drug Class, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, 2020-2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Drug Class, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, 2020-2032, (US$ Mn)
  - South Africa
  - Central Africa
  - North Africa

8. Competitive Landscape

Company Profiles
- Ipca Laboratories Ltd.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Zydus Group
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Merck KGaA
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- GSK plc.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Cipla Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sun Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Alvizia Health Care
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bayer AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- F. Hoffmann-La Roche Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies

9. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

抗疟疾药市场按药物类别、给药途径、分销管道和地区划分